Digoxin Antibody (Mouse Monoclonal)

Product Description

Monoclonal Antibody to Digoxin

References

• Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP; ORBIT-AF Investigators. J Am Coll Cardiol. 2015 Jun 30;65(25):2691-8.
• Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Drugs Aging. 2011 Oct 1;28(10):831-41.
• Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Jelliffe RW. Ther Drug Monit. 2012 Aug;34(4):368-77.
• Serum glycoside concentrations after single or repeated intravenous doses of beta-methyl-digoxin and digoxin. Marinow J, Olcay A, Schaumann W, Weiss W. Eur J Clin Pharmacol. 1977 Mar 11;11(3):213-8.
• Cross reactivity of the EMIT digoxin assay with digoxin metabolites, and validation of the method for measurement of urinary digoxin. Linday L, Drayer DE. Clin Chem. 1983 Jan;29(1):175-7.
• Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. Englund G, Hallberg P, Artursson P, Michaëlsson K, Melhus H. BMC Med. 2004 Apr 2;2:8. doi: 10.1186/1741-7015-2-8.
• Effect of physical exercise on the pharmacokinetics of digoxin during maintenance treatment. Jogestrand T, Andersson K. J Cardiovasc Pharmacol. 1989 Jul;14(1):73-6.

Related Products